Navigation Links
Renaissance Laser & Vein Institute (LaserandVeinclinic.com) 'Pearl Treatment'
Date:1/26/2009

With Pearl you can get a more aggressive treatment for facial lines, texture and pigmentation without the lengthy downtime

THOUSAND OAKS, Calif., Jan. 26 /PRNewswire/ -- The Pearl procedure is used for the treatment of wrinkles, uneven skin texture, sun-damaged skin and aging to provide a healthy, pearl-like glow. By applying gentle pulses of light in a pre selected pattern, the laser concurrently sends heat to the deeper layers of skin for long-term benefits. The treatment will feel like a series of brief pinches on the skin and the pain is minimal. Remarkably, the treatment is safe and effective for all skin types.

Unlike other treatments, the Pearl treatment will minimize the down time of restorative process by using a natural protective dressing that acts as a thin layer on the surface of the skin. This dressing will peel off from the skin on the third or fourth day, leaving a vibrant, healthy, and new skin underneath. After this time, you can see the rejuvenation results and even be able to apply makeup. The Pearl treatment is also the only office laser treatment that can be used to treat the lower eyelids.

The Renaissance Laser & Vein Institute is the first center in the Conejo Valley to offer the Pearl Procedure, and is one of a very few sites in Southern California where this technology can be accessed. Dr. Kouros Azar, a Board Certified Plastic Surgeon and one of the founding members of Renaissance Laser and Vein Institute was one of the very first doctors in California to have experience with using the Pearl in an expert fashion on many patients. He has traveled extensively throughout the U.S. and Canada sharing his experience and knowledge with other doctors. For maximum skin enhancement, you may benefit from their combination therapies including IPL Photofacial and Pearl for complete removal of sun spots and damage as well as fine lines and texture issues. Another revolutionary combination the
'/>"/>

SOURCE Renaissance Laser & Vein Institute
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc.
2. Renaissance Health Publishing, LLC Warns the Public that ConsumerLab.com is Not Independent and Labels the CL Seal of Approval a Worthless, Paid-For Advertising Gimmick
3. Renaissance Health Publishing, LLC Asks Key Credibility Questions of ConsumerLab.com
4. ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing
5. MedX Health Announces Initiation of Laser Acupuncture Study for Controlling Addiction
6. An Evolution in Automated CO2 Laser Surgery
7. Jeylan El-Mansoury, MD of Jardin Medical Spa Announced Today That They Have Purchased the 1st Revage 670(TM) Hair Regeneration Laser in the Greater Philadelphia Area
8. Juva Skin Center's Laser Skin Treatments Take an Innovative Leap with Pixel CO2 Device
9. Barotz Dental Now Offering Laser Gum Therapy
10. Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available
11. HOYA ConBio(TM) Introduces VersaWave(R) Specialty Laser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... The Global Allopurinol Industry Report 2015 ... current state of the Allopurinol industry.With 147 tables ... the state of the industry and is a ... and individuals interested in the market. The report ... definitions, classifications, applications and industry chain structure. The ...
(Date:5/29/2015)... Designed with the versatile athlete in ... an all new, exclusive line of supplementation called The ... latest and greatest, high impact, result driven ingredients that ... The 24/7 Series can be used by anyone from ... casual fitness enthusiasts. There are no stimulant based ingredients ...
(Date:5/29/2015)... VA (PRWEB) May 29, 2015 Javlin ... a new U.S. headquarters and a larger team, with ... and increase CloverETL's market share in the U.S. and ... the Javlin Group, achieved significant growth in 2014 with ... of Javlin’s premier data integration platform, CloverETL. To accelerate ...
(Date:5/29/2015)... This is a professional and ... Naproxen industry.The report provides a basic overview of ... chain structure. The Naproxen market analysis ... trends, competitive landscape analysis, and key regions development ... as manufacturing processes and cost structures are also ...
(Date:5/29/2015)... Michigan (PRWEB) May 29, 2015 Vulvodynia ... and can cause significant physical, sexual, and psychological distress. ... altering disorder of Vulvodynia. The actual diagnosis is often ... in Endometriosis, they realize that this problem can be ... experiencing any of these symptoms, they need to schedule ...
Breaking Medicine News(10 mins):Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... Regions, These Markets Remain Stable, According to New ... HealthLeaders-InterStudy, a leading provider of managed care ... many regions of the country have halted because ... in Buffalo, N.Y., and Baton Rouge, La., are ...
... Calif., Jan. 26 Doctors at the,Northwoods Cancer ... patients,using new RapidArc radiotherapy technology from Varian Medical ... a retired machinist fighting prostate cancer, is,among the ... speed and accuracy of,RapidArc, which delivers image-guided intensity-modulated ...
... Jan. 26 ChromaDex Corporation, (OTC Bulletin Board: ... contract research, announced today that Nutrition Business Journal, ... care magazine, selected the Company as one of ... its achievement in setting stevia standards as part ...
... will add new technology to help ORBIS train doctors ... ORBIS International , a nonprofit ... donated PASCAL photocoagulator as part of a new partnership ... to treat a variety of retinal diseases, PASCAL dramatically ...
... Jan. 26 FluoroPharma Inc., a company ... Positron Emission Tomography (PET) market, announced today ... Office issued U.S. Patent No. 7,438,891, covering ... F18 labeled 2-fluorodeoxy-D-glucose (FDG). This patent, exclusively ...
... N.J., Jan. 26 Quest Diagnostics Incorporated (NYSE: ... of diagnostic testing, information and services, announced that ... in share repurchases. The company had approximately 190 ... 2008."This repurchase program demonstrates confidence in our performance ...
Cached Medicine News:Health News:Hospital Expansions in Buffalo, N.Y., and Baton Rouge, La., Contribute to Recession Resilience 2Health News:Hospital Expansions in Buffalo, N.Y., and Baton Rouge, La., Contribute to Recession Resilience 3Health News:A Fast, New Cancer Fighting Tool Is Now Available in the Houston Area: RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 2Health News:A Fast, New Cancer Fighting Tool Is Now Available in the Houston Area: RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 3Health News:ChromaDex Awarded Nutrition Business Journal Scientific Achievement 2Health News:ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica 2Health News:ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica 3Health News:ORBIS International Receives Donated PASCAL(R) Photocoagulator From OptiMedica 4Health News:FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG 2Health News:Quest Diagnostics' Board Authorizes $500 Million in Share Repurchases 2
(Date:5/29/2015)... MENLO PARK, Calif. , May ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, presented ... of Cancer Research (AACR) Advances in Brain Cancer ... lead product candidate VAL-083 (dianhydrogalactitol) to ...
(Date:5/29/2015)... 29, 2015 Amgen (NASDAQ: AMGN ... Phase 3, global, randomized, placebo-controlled trials evaluating AMG ... secondary hyperparathyroidism (SHPT) in patients with chronic kidney ... primary endpoint, demonstrating that a greater proportion of ... greater than 30 percent reduction in parathyroid hormone ...
(Date:5/28/2015)... and Company (NYSE: LLY ) announced today the pricing ... to $1.6 billion aggregate principal amount of certain of its ... and did not validly withdraw, their notes on or before ... on May 27, 2015 (the early tender date), and which ... the total consideration. The total consideration for each series of ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... PITTSBURGH, Dec. 16 Cohera Medical Inc. today announced ... of its lead surgical adhesive product, TissuGlu®. Initiation of ... progression of the lead product toward clinical practice. ... study to investigate the safety of TissuGlu and its ...
... , , INDIANAPOLIS, Dec. 16 RealMed has been ranked ... Top 20 Best in KLAS Awards: Software & Professional Services ... providing advanced, online, automated transactions processing between healthcare providers and ... specializing in vendor performance measurement in the software, professional services, ...
Cached Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3
Claes Shielded Retinotomy Scissors, Vertical...
Indirect hemagglutination assay (IHA) for the detection and semi-quantitation of human antibodies to the bacteria of the genus Leptospira. Each kit contains test cells, control cells, and positive an...
... antibody (IFA) test for ... of human serum IgG ... capsid antigen (VCA). Each ... slides, FITC IgG conjugate, ...
... (IFA) test for the detection and ... to the detection and semi-quantitation of ... early antigens, both restricted (R) and ... 12-well slides, FITC conjugate, positive and ...
Medicine Products: